HLB Life Science Balance Sheet Health
Financial Health criteria checks 4/6
HLB Life Science has a total shareholder equity of ₩231.2B and total debt of ₩165.2B, which brings its debt-to-equity ratio to 71.5%. Its total assets and total liabilities are ₩423.5B and ₩192.3B respectively.
Key information
71.5%
Debt to equity ratio
₩165.23b
Debt
Interest coverage ratio | n/a |
Cash | ₩78.86b |
Equity | ₩231.21b |
Total liabilities | ₩192.29b |
Total assets | ₩423.50b |
Recent financial health updates
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10Recent updates
HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up
Mar 15HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
Feb 14Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings
Dec 06Financial Position Analysis
Short Term Liabilities: A067630's short term assets (₩99.5B) do not cover its short term liabilities (₩135.5B).
Long Term Liabilities: A067630's short term assets (₩99.5B) exceed its long term liabilities (₩56.8B).
Debt to Equity History and Analysis
Debt Level: A067630's net debt to equity ratio (37.4%) is considered satisfactory.
Reducing Debt: A067630's debt to equity ratio has increased from 45.5% to 71.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A067630 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A067630 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 17.4% each year